Separation and study of the range of plasminogen isoforms in patients with prostate cancer

• Published in: Biochemistry (Moscow) Vol. 77; no. 9; pp. 1065 - 1071
• Main Authors: Shin, E. F., Vodolazhsky, D. I., Golikov, A. Yu, Belova, T. N., Boyko, N. V., Zimakov, D. V., Cherkasova, E. N., Kogan, M. I., Chibichian, M. B., Moshkovskii, S. A., Tarasov, V. A., Matishov, D. G.
• Format: Journal Article
• Language: English
• Published: Dordrecht SP MAIK Nauka/Interperiodica 01.09.2012; Springer; Springer Nature B.V
• Subjects: Aged; Biochemistry; Biomedical and Life Sciences; Biomedicine; Bioorganic Chemistry; Cancer; Cancer patients; Care and treatment; Developmental stages; Glycoproteins; Humans; Life Sciences; Male; Mass spectrometry; Microbiology; Middle Aged; Oncology, Experimental; Plasma; Plasminogen - analysis; Plasminogen - isolation & purification; Prostate cancer; Prostatic Neoplasms - blood; Proteases; Protein Isoforms - blood; Proteins; Thrombolytic drugs; two-dimensional electrophoresis; MALDI-TOF-MS; prostate cancer; plasminogen isoforms
• ISSN: 0006-2979; 1608-3040
• DOI: 10.1134/S0006297912090143

Using affinity chromatography, two-dimensional electrophoresis, and MALDI-TOF mass spectrometry, plasminogen isoforms were separated and identified in blood plasma. Healthy donors and patients with prostate cancer in various stages of development were included in the studied sample. With the development of prostate cancer, four additional specific plasminogen isoforms are registered in blood plasma; they are characterized by lower molecular weights and higher p I values compared to isoforms found in the control group.